Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Similar articles for PubMed (Select 16383350)

1.

New approaches to vaccine adjuvants: inhibiting the inhibitor.

Graham BS.

PLoS Med. 2006 Jan;3(1):e57. Epub 2006 Jan 3. No abstract available.

2.

An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells.

Song XT, Evel-Kabler K, Rollins L, Aldrich M, Gao F, Huang XF, Chen SY.

PLoS Med. 2006 Jan;3(1):e11. Epub 2006 Jan 3.

3.

Adjuvanted vaccine strategies and live vector approaches for the prevention of AIDS.

Voss G, Villinger F.

AIDS. 2000;14 Suppl 3:S153-65. Review. No abstract available.

PMID:
11086858
4.

Immunostimulatory combinations: designing the next generation of vaccine adjuvants.

Kornbluth RS, Stone GW.

J Leukoc Biol. 2006 Nov;80(5):1084-102. Epub 2006 Aug 24. Review.

5.

Cytokines as adjuvants for improving anti-HIV responses.

Morrow MP, Weiner DB.

AIDS. 2008 Jan 30;22(3):333-8. doi: 10.1097/QAD.0b013e3282f42461. Review. No abstract available.

PMID:
18195559
6.

Cytokine-adjuvanted HIV-DNA vaccination strategies.

Lori F, Weiner DB, Calarota SA, Kelly LM, Lisziewicz J.

Springer Semin Immunopathol. 2006 Nov;28(3):231-8. Epub 2006 Oct 20. Review.

PMID:
17053912
7.

Suppressor of cytokine signaling 1 inhibition strategy to enhance anti-HIV vaccination.

Song XT, Aldrich M, Chen SY.

Expert Rev Vaccines. 2006 Aug;5(4):495-503. Review.

PMID:
16989630
8.

Immunization and challenge of chimpanzees with HIV-1.

Fultz PN.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1517-9. No abstract available.

PMID:
1466994
9.

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.

Caputo A, Brocca-Cofano E, Castaldello A, Voltan R, Gavioli R, Srivastava IK, Barnett SW, Cafaro A, Ensoli B.

Vaccine. 2008 Feb 26;26(9):1214-27. doi: 10.1016/j.vaccine.2007.12.030. Epub 2008 Jan 15.

PMID:
18243435
10.

A boost for the immune system.

[No authors listed]

TreatmentUpdate. 1998 Nov;10(9):3-4. English, French.

PMID:
11365925
11.

Advances in vaccine adjuvants for infectious diseases.

Singh M, Srivastava I.

Curr HIV Res. 2003 Jul;1(3):309-20. Review.

PMID:
15046255
12.

Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.

Ahlers JD, Belyakov IM.

Trends Mol Med. 2009 Jun;15(6):263-74. doi: 10.1016/j.molmed.2009.04.003. Epub 2009 May 30. Review.

PMID:
19487159
13.

Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.

Shinoda K, Xin KQ, Kojima Y, Saha S, Okuda K, Okuda K.

Clin Immunol. 2006 Apr;119(1):32-7. Epub 2006 Feb 2.

PMID:
16458074
14.

The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.

Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA.

Vaccine. 2009 Aug 13;27(37):5077-84. doi: 10.1016/j.vaccine.2009.06.046. Epub 2009 Jun 30.

PMID:
19573639
15.

Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.

Bråve A, Hallengärd D, Schröder U, Blomberg P, Wahren B, Hinkula J.

Vaccine. 2008 Sep 19;26(40):5075-8. doi: 10.1016/j.vaccine.2008.03.066. Epub 2008 Apr 15.

PMID:
18450334
16.

Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?

Egan MA.

Expert Rev Vaccines. 2007 Jun;6(3):289-91. No abstract available.

PMID:
17542741
17.

Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.

Rollman E, Mathy N, Bråve A, Boberg A, Kjerrström A, van Wely C, Engström G, Johansson S, Aperia K, Eriksson LE, Benthin R, Ertl P, Heeney J, Hinkula J, Voss G, Wahren B.

Vaccine. 2007 Mar 1;25(11):2145-54. Epub 2006 Nov 13.

PMID:
17254672
18.

Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination.

Aline F, Brand D, Pierre J, Roingeard P, Séverine M, Verrier B, Dimier-Poisson I.

Vaccine. 2009 Aug 20;27(38):5284-91. doi: 10.1016/j.vaccine.2009.05.028. Epub 2009 May 29.

PMID:
19450633
19.

Progress and obstacles in the development of an AIDS vaccine.

Letvin NL.

Nat Rev Immunol. 2006 Dec;6(12):930-9. Review.

PMID:
17124514
20.

DCs for HIV vaccine?

[No authors listed]

Nat Rev Microbiol. 2007 Mar;5(3):172. No abstract available.

PMID:
17310536
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk